Molecular Pharmacology Program

The Neal Rosen Lab

Neal Rosen, MD, PhD

The main goal of our laboratory is the identification and characterization of signal transduction pathways that cause the dysregulation of growth and inhibition of apoptosis that characterize advanced human cancer. Our laboratory is dedicated to understanding the consequences of activation of these pathways and to using this information to develop mechanism-based therapeutic strategies.

View Lab Overview

Research Projects

Kinase Inhibitors

Featured News

In the Clinic

Piro Lito, Bob Li, and Neal Rosen in the lab

Promising Results from the First-Ever Trial of a Drug that Blocks Cancer Gene KRAS

The drug, sotorasib, is targeted against a cancer-causing protein that has long been considered an “undruggable” target.

In the Lab

Knocking Out KRAS-Mutant Cancers with a One-Two Punch

A new approach aims to combine two existing targeted therapy drugs to attack lung cancer and pancreatic cancer with mutations in the hard-to-target gene KRAS.

In the Lab

New Lung Cancer Therapy May Target Previously Untreatable Tumors

Researchers are developing uses for a drug that could benefit many people with lung cancer.

View All Featured News

Publications Highlights

Lee BJ, Boyer JA, Burnett GL, Thottumkara AP, Tibrewal N, Wilson SL, Hsieh T, Marquez A, Lorenzana EG, Evans JW, Hulea L, Kiss G, Liu H, Lee D, Larsson O, McLaughlan S, Topisirovic I, Wang Z, Wang Z, Zhao Y, Wildes D, Aggen JB, Singh M, Gill AL, Smith JAM, Rosen N. Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth. Nat Chem Biol. 2021 Oct;17(10):1065-1074. doi: 10.1038/s41589-021-00813-7. Epub 2021 Jun 24. Erratum in: Nat Chem Biol. 2021 Jun 29;: Erratum in: Nat Chem Biol. 2021 Nov;17(11):1209. PMID: 34168367.

Mukherjee R, Vanaja KG, Boyer JA, Gadal S, Solomon H, Chandarlapaty S, Levchenko A, Rosen N. Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. Mol Cell. 2021 Feb 18;81(4):708-723.e5. doi: 10.1016/j.molcel.2021.01.033. PMID: 33606974; PMCID: PMC8384339.

Yao, Z., Gao, Y., Su, W., Yaeger, R., Tao, J., Na, N., Zhang, Y., Zhang, C., Rymar, A., Tao, A., Timaul, N. M., Mcgriskin, R., Outmezguine, N. A., Zhao, H., Chang, Q., Qeriqi, B., Barbacid, M., de Stanchina, E., Hyman, D. M., Bollag, G., … Rosen, N. (2019). RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nature medicine, 25(2), 284–291. https://doi.org/10.1038/s41591-018-0274-5

Gao, Y., Chang, M. T., McKay, D., Na, N., Zhou, B., Yaeger, R., Torres, N. M., Muniz, K., Drosten, M., Barbacid, M., Caponigro, G., Stuart, D., Moebitz, H., Solit, D. B., Abdel-Wahab, O., Taylor, B. S., Yao, Z., & Rosen, N. (2018). Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer discovery, 8(5), 648–661. https://doi.org/10.1158/2159-8290.CD-17-1452

Yaeger, R., Chatila, W. K., Lipsyc, M. D., Hechtman, J. F., Cercek, A., Sanchez-Vega, F., Jayakumaran, G., Middha, S., Zehir, A., Donoghue, M., You, D., Viale, A., Kemeny, N., Segal, N. H., Stadler, Z. K., Varghese, A. M., Kundra, R., Gao, J., Syed, A., Hyman, D. M., … Schultz, N. (2018). Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer cell, 33(1), 125–136.e3. https://doi.org/10.1016/j.ccell.2017.12.004

View All Publications

People

Neal Rosen, MD, PhD

Pharmacologist Neal Rosen focuses on understanding biochemical mechanisms underlying phenotypes caused by tyrosine kinase activation in epithelial tumors and developing new therapeutic strategies.
MD, PhD, Albert Einstein College of Medicine

[email protected]: Email Address
646-888-2075: Office Phone
View physician profile: Physician profile

Members

Jacob A. Boyer
Ludwig Princeton Scholar in Cancer Metabolism at Princeton University, Princeton, NJ

Philip Choi

Instructor

Esther Kaplun

Research Technician

Michelangelo Marasco

Research Fellow

Priya Pancholi

Research Assistant

Malvika Sharma

Research Fellow

Lab Alumni

Liqun Cai

Former Research Technician

Sarat Chandarlapaty

Assistant Member, Human Oncology and Pathogenesis Program; Department of Medicine, Memorial Sloan Kettering Cancer Center

Poulikos Poulikakos

Assistant Professor, Mount Sinai

Andreja Jovic

Research Fellow

Qing-Bai She

Faculty, University of Kentucky

Piro Lito
Enid A. Haupt Chair in Therapeutic Research

David Solit

Director, Developmental Therapeutics; Associate Professor of Medicine; Cell and Developmental Biology, Memorial Sloan Kettering Cancer Center

Oren Litvin

Former Graduate Student

Christine A. Pratilas

Assistant Attending, Department of Pediatrics

Sarit Schwartz

Research Fellow

Martha Solomon

Research Technician

Sharmeen Uddin

Former Research Technician

Marie Will

Former Graduate Student

Paige Yellen

Research Fellow

Jingyin Yue

Former Research Fellow

Arpitha Banaji

Research Technician

Yu Bian

Former Research Technician

Laura Desrochers

Research Fellow

Alessandria Greco

Research Technician

Keven Muniz

Lab Technician

Jason Reiter

Research Technician

Vanessa Rodrik-Outmezguine
Senior Scientist

Alberto Vides

Research Technician

Rona Yaeger
Assistant Attending Physician, Department of Medicine

Lab Affiliations

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Postdoctoral Positions

Apply now

Get in Touch

[email protected]

Lab Head Email
646-888-2075

Office Phone

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Neal Rosen discloses the following relationships and financial interests:

BeiGene, Ltd.
Equity; Professional Services and Activities
Chugai Pharmaceuticals
Professional Services and Activities
eFFECTOR Therapeutics
Equity
Fortress Biotech Inc
Equity
Ikena Oncology
Professional Services and Activities
Jubilant Therapeutics Inc.
Professional Services and Activities (Uncompensated)

Kura Oncology
Equity
Lutris Pharma Ltd.
Intellectual Property Rights
MapKure LLC
Equity; Professional Services and Activities
Revolution Medicines
Professional Services and Activities (Uncompensated)
Ribon Therapeutics
Professional Services and Activities
Zai Lab
Equity; Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures